Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study

Ignace Vergote,Els Van Nieuwenhuysen,Roisin E O'Cearbhaill,Anneke Westermann,Domenica Lorusso,Sharad Ghamande,Dearbhaile C Collins,Susana Banerjee,Cara A Mathews,Christine Gennigens,David Cibula,Krishnansu S Tewari,Kristine Madsen,Fatih Köse,Amanda L Jackson,Ingrid A Boere,Giovanni Scambia,Leslie M Randall,Azmat Sadozye,Jean-François Baurain,Eelke Gort,Michal Zikán,Hannelore G Denys,Nelleke Ottevanger,Frédéric Forget,Camilla Mondrup Andreassen,Lamar Eaton,Michael J Chisamore,Leonardo Viana Nicacio,Ibrahima Soumaoro,Bradley J Monk,Roisin E. O'Cearbhaill,Dearbhaile C. Collins,Cara A. Mathews,Krishnansu S. Tewari,Amanda L. Jackson,Ingrid A. Boere,Leslie M. Randall,Hannelore G. Denys,Michael J. Chisamore,Bradley J. Monk

DOI: https://doi.org/10.1200/JCO.23.00720

IF: 45.3

2023-09-01

Journal of Clinical Oncology

Abstract:PURPOSE Tissue factor is highly expressed in cervical carcinoma and can be targeted by tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV in combination with bevacizumab, pembrolizumab, or carboplatin for recurrent or metastatic cervical cancer (r/mCC). METHODS This open-label, multicenter study (ClinicalTrials.gov identifier: NCT03786081 ) included dose-escalation arms that assessed dose-limiting toxicities (DLTs) and identified the recommended phase II dose (RP2D) of TV in combination with bevacizumab (arm A), pembrolizumab (arm B), or carboplatin (arm C). The dose-expansion arms evaluated TV antitumor activity and safety at RP2D in combination with carboplatin as first-line (1L) treatment (arm D) or with pembrolizumab as 1L (arm E) or second-/third-line (2L/3L) treatment (arm F). The primary end point of dose expansion was objective response rate (ORR). RESULTS A total of 142 patients were enrolled. In dose escalation (n = 41), no DLTs were observed; the RP2D was TV 2 mg/kg plus bevacizumab 15 mg/kg on day 1 once every 3 weeks, pembrolizumab 200 mg on day 1 once every 3 weeks, or carboplatin AUC 5 on day 1 once every 3 weeks. In dose expansion (n = 101), the ORR was 54.5% (n/N, 18/33; 95% CI, 36.4 to 71.9) with 1L TV + carboplatin (arm D), 40.6% (n/N, 13/32; 95% CI, 23.7 to 59.4) with 1L TV + pembrolizumab (arm E), and 35.3% (12/34; 19.7 to 53.5) with 2L/3L TV + pembrolizumab (arm F). The median duration of response was 8.6 months, not reached, and 14.1 months, in arms D, E, and F, respectively. Grade ≥3 adverse events (≥15%) were anemia, diarrhea, nausea, and thrombocytopenia in arm D and anemia in arm F (none ≥15%, arm E). CONCLUSION TV in combination with bevacizumab, carboplatin, or pembrolizumab demonstrated manageable safety and encouraging antitumor activity in treatment-naive and previously treated r/mCC.

oncology